Mankind Pharma Ltd

Mankind Pharma Ltd’s shares declined to a fresh 52-week low of Rs.2029.35 on 6 Feb 2026, marking a significant drop amid a three-day losing streak that has seen the stock fall by 4.87%. This decline comes despite the broader Sensex trading near its 52-week high, highlighting company-specific pressures within the Pharmaceuticals & Biotechnology sector.

Mankind Pharma Ltd (MANKIND) witnessed a significant 27.8% surge in open interest in its derivatives segment on 4 Feb 2026, signalling heightened market activity and shifting investor positioning. This spike comes amid a volatile trading session where the stock underperformed its sector and approached its 52-week low, raising questions about directional bets and future price momentum.

Mankind Pharma Ltd has witnessed a significant surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This increase comes amid a backdrop of notable price volatility and underperformance relative to its sector peers, raising questions about potential directional bets and market sentiment towards the large-cap pharmaceutical stock.

Mankind Pharma Ltd (MANKIND) witnessed a significant surge in open interest (OI) in its derivatives segment on 4 Feb 2026, signalling heightened market activity and shifting investor positioning. The stock, trading close to its 52-week low, experienced a 26.6% increase in OI alongside elevated volumes, reflecting a complex interplay of directional bets amid a volatile trading session.

Mankind Pharma Ltd has witnessed a significant 26.8% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this spike, the stock underperformed its sector and broader indices, trading near its 52-week low and reflecting bearish sentiment among traders.

Mankind Pharma Ltd has witnessed a significant 16.5% rise in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This surge accompanies a notable price decline, with the stock closing near its 52-week low and underperforming its sector, raising questions about the underlying directional bets and market sentiment.

Mankind Pharma Ltd experienced a notable intraday decline on 4 February 2026, touching a low of Rs 2,081, reflecting a 3.47% drop from its opening levels. The stock underperformed its sector and broader market indices, weighed down by persistent selling pressure and subdued market sentiment.

Mankind Pharma Ltd., one of India's leading pharmaceutical companies with a market capitalisation of ₹87,785 crores, delivered a mixed performance in Q3 FY26 (October-December 2025), with consolidated net profit rising 7.50% year-on-year to ₹408.75 crores but declining 20.09% sequentially from ₹511.51 crores in Q2 FY26. The stock surged 4.30% to ₹2,155.90 following the results announcement, though it remains down 16.56% over the past year, significantly underperforming both the Sensex and the pharmaceutical sector.

Mankind Pharma Ltd has witnessed a significant 26.3% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a strong intraday performance and outperformance relative to its sector, the stock faces mixed technical indicators and a recent downgrade in its mojo rating, prompting a nuanced outlook for traders and investors alike.

Mankind Pharma Ltd (MANKIND) witnessed a significant 17.5% increase in open interest in its derivatives segment on 3 Feb 2026, signalling heightened market interest and potential directional bets. The stock outperformed its sector and broader indices, supported by a notable volume surge and positive price action, despite mixed moving average signals and declining delivery volumes.

Mankind Pharma Ltd demonstrated robust intraday performance on 3 Feb 2026, surging to an intraday high of Rs 2,152.5, marking a 4.13% increase from the previous close. The stock outpaced its sector and broader market indices, reflecting notable trading momentum amid a mixed market backdrop.

Mankind Pharma Ltd’s shares declined to a fresh 52-week low of Rs.2053 today, marking a significant milestone in the stock’s recent performance. This new low reflects ongoing pressures on the company’s valuation amid subdued profit growth and valuation concerns within the Pharmaceuticals & Biotechnology sector.

Mankind Pharma Ltd has witnessed a notable 10.75% increase in open interest in its derivatives segment, signalling heightened market activity despite the stock trading near its 52-week low. This surge in open interest, coupled with volume patterns and price movements, offers insights into evolving market positioning and potential directional bets among investors.

Mankind Pharma Ltd’s shares declined to a fresh 52-week low of Rs.2060 on 27 Jan 2026, marking a significant price level amid a broader market downturn. The stock has underperformed its sector and key indices, reflecting a combination of subdued financial results and valuation concerns.

Mankind Pharma Ltd is rated Sell by MarketsMOJO, with this rating last updated on 19 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 January 2026, providing investors with the latest insights into the company’s performance and outlook.